Cardiotoxicity due to cancer therapy.

The convergence of novel molecular techniques for the study of cardiovascular disease—together with the development of an armamentarium of molecular-targeted anticancer therapies—is fueling the interest of molecular cardiologists in probing the mechanisms of cancer-therapy–induced cardiac toxicity. Such studies have the potential to develop strategies that will prevent cardiac toxicity from becoming a barrier to effective anticancer therapy. They might also provide novel insights into the pathogenesis of non-cancer-therapy–induced human heart disease.